Improved Induction of Melanoma-Reactive CTL with Peptides from the Melanoma Antigen gp100 Modified at HLA-A*0201-Binding Residues

Journal of Immunology

Volumn 157, Issue 6, 1996, Pages 2539-2548

  Parkhurst, Maria R ^a   Salgaller, Michael L ^a   Southwood, Scott ^b   Robbins, Paul F ^a   Sette, Alessandro ^b   Rosenberg, Steven A ^a   Kawakami, Yutaka ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CYTEL CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA A ANTIGEN; MELANOCYTE LINEAGE SPECIFIC ANTIGEN GP100; MELANOCYTE LINEAGE-SPECIFIC ANTIGEN GP100; MEMBRANE PROTEIN; PEPTIDE FRAGMENT; TUMOR ANTIGEN; TUMOR PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; CHEMISTRY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG EFFECT; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MELANOMA; PROTEIN BINDING; SKIN TUMOR; TUMOR ASSOCIATED LEUKOCYTE;

AMINO ACID SEQUENCE; ANTIGENS, NEOPLASM; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES; HLA-A ANTIGENS; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; PROTEIN BINDING; SKIN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0030587077     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Rosenberg, S., B. Packard, P. Aebersold, D. Solomon, S. Topalian, S. Toy, P. Simon, M. Lotze, J. Yang, C. Seipp, C. Simpson, C. Carter, S. Bock, D. Schwartzentruber, J. Wei, and D. While. 1988. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: preliminary report. N. Engl. J. Med. 319:1676.
2. Rosenberg, S. A. 1992. The immunotherapy and gene therapy of career. J. Clin. Oncol. 10:180.
3. Rosenberg, S., J. Yannelli, J. Yang, S. Topalian, D. Schwartzentruber, J. Weber, D. Parkinson, C. Seipp, J. Einhorn, and D. White, 1994. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin-2. J. Natl. Cancer Inst. 86:1159.
4. Darrow, T., C. Slingluff, and H. Seigler. 1989. The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes: evidence for shared tumor antigens. J. Immunol. 142:3329.
5. Hom, S., S. Topalian, S. Simoni, M. Mancini, and S. Rosenberg. 1991. Common expression of melanoma tumor-associated antigens recognized by human tumor-infiltrating lymphocytes: analysis by human lymphocyte antigen restriction. J. Immunother. 10:153.
6. Kawakami, Y., R. Zakut, S. Topalian, H. Stotter, and S. Rosenberg. 1992. Shared human melanoma antigens: recognition by tumor infiltrating lymphocytes in HLA-A2.1 transfected melanomas. J. Immunol. 148:638.
7. Hom, S., S. Schwartzentruber, S. Rosenberg, and S. Topalian. 1993. Specific release of cytokines by lymphocyte infiltrating human melanomas in response to shared melanoma antigens. J. Immunother. 13:18.
8. O'Neil, B., Y. Kawakami, N. Restifo, J. Bennink, J. Yewdell, and S. Rosenberg. 1993. Detection of shared MHC-restricted human melanoma antigens after vaccinia virus-mediated transduction of genes coding for HLA. J. Immunol. 151: 1410.
9. Anichini, A., C. Maccalli, R. Mortarini, S. Salvi, A. Mazzocchi, P. Squarcina, M. Herlyn, and G. Parmiani. 1993. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2 restricted cytotoxic T cell clones from melanoma patients. J. Exp. Med. 177:989.
10. Kawakami, Y., S. Eliyahu, C. Delgado, P. Robbins, L. Rivoltini, S. Topalian, T. Miki, and S. Rosenberg. 1994. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA 91:3515.
11. Coulie, P., V. Brichard, A. Van Pel, T. Wölfel, J. Schneider, C. Traversari, S. Mattei, E. DePlaen, C. Lurquin, J. Szikora, J. Renault, and T. Boon. 1994. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180:1.
12. Bakker, A., M. Schreurs, A. deBoer, Y. Kawakami, S. Rosenberg, G. Adema, and C. Figdor. 1994. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med. 179:1005.
13. Kawakami, Y., S. Eliyahu, C. Delgado, P. Robbins, K. Sakaguchi, E. Appella, J. Yannelli, G. Adema, T. Miki, and S. Rosenberg. 1994. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA 91:6458.
14. Brichard, V., A. Van Pel, T. Wölfel, C. Wölfel, E. DePlaen, B. Lethe, P. Coulie, and T. Boon. 1993. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanoma. J. Exp. Med. 178: 489.
15. Robbins, P., M. El-Gamil, Y. Kawakami, E. Stevens, J. Yannelli, and S. Rosenberg. 1994. Recognition of tyrosinase by tumor infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res. 54:3124.
16. Wang, R., P. Robbins, Y. Kawakami, X. Kang, and S. Rosenberg. 1995. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor infiltrating lymphocytes. J. Exp. Med. 181:799.
17. Robbins, P., M. El-Gamil, Y. Li, S. Topalian, L. Rivoltini, K. Sakaguchi, E. Appella, Y. Kawakami, and S. Rosenberg. 1995. Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24 restricted tumorinfiltrating lymphocytes. J. Immunol. 154:5944.
18. Robbins, P., M. El-Gamil, Y. Li, Y. Kawakami, D. Loftus, E. Appella, and S. A. Rosenberg. 1995. A mutated β catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. in press.
19. Kawakami, Y., S. Eliyahu, C. Jennings, K. Sakaguchi, X. Kang, S. Southwood, P Robbins, A. Sette, E. Appella, and S. Rosenberg. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 154:3961.
20. Cox, A., J. Skipper, Y. Cehn, R. Henderson, T. Darrow, J. Shabanowitz, V. Engelhard, D. Hunt, and C. Slingluff. 1994. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264:716.
21. Bakker, A., M. Schreurs, G. Tafazzul, A. DeBoer, Y. Kawakami, G. Adema, and C. Figdor. 1995. Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line. Int. J. Cancer 62:97.
22. Salgaller, M., A. Afshar, F. Marincola, L. Rivotini, Y. Kawakami, and S. Rosenberg. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res. 55:4972.
23. Sette, A., A. Vitiello, B. Reherman, P. Fowler, R. Nayersina, W. Kast, C. Melief, C. Oseroff, L. Yuan, J. Ruppert, J. Sidney, M. del Guercio, S. Southwood, R. Kubo, R. Chesnut, H. Grey, and F. Chisari. 1994. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol. 153:5586.
24. Lipford, G., S. Bauer, H. Wagner, and K. Heeg. 1995. In vivo CTL induction with point-substituted ovalbumin peptides: immunogenicity correlates with peptide-induced MHC class I stability. Vaccine 13:313.
25. Chen, W., S. Khilko, J. Fecondo, D. Margulies, and J. McCluskey. 1994. Determinant selection of major histocompatibility complex class I-restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by nondominant anchor residues. J. Exp. Med. 180:1471.
26. Parker, K., M. Bednarek, L. Hull, U. Utz, B. Cunningham, J. Zweering, W. Biddison, and J. Coligan. 1992. Sequence motifs important for peptide binding to the human MHC class I molecule. HLA-A2. J. Immunol. 149:3580.
27. Falk, K., O. Rotzschke, S. Sevanovic, G. Jung, and J. Rammensee. 1991. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351:290.
28. Ruppert, J., J. Sidney, E. Celis, R. Kubo, H. Grey, and A. Sette. 1993. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules Cell 74:929.
29. Kubo, R., A. Sette, H. Grey, E. Appella, K. Sakaguchi, N. Zhu, D. Arnott, N. Sherman, J. Shabanowitz, H. Michel, W. Bodnar, T. Davis, and D. Hunt. 1994. Definition of specific peptide motifs for four major HLA-A alleles. J. Immunol. 152:3913.
30. Rammensee, H., R. Friede, and S. Stevanovic. 1995. MHC ligands and peptide molifs: first listing. Immunogenetics 41:178.
31. Hunt, D., R. Henderson, J. Shabanowitz, K. Sakaguchi, H. Michel, N. Sevilir, A. Cox, E. Appella, and V. Engelhard. 1992. Characterization of peptides bound to the class 1 MHC molecule HLA-A2.1 by mass spectrometry. Science 255: 1261.
32. Kast, W., R. Brandt, J. Sidney, S. Drijfhout, R. Kubo, H. Grey, C. Melief, and A. Sette. 1994. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J. Immunol. 152:3904.
33. Lipford, G., S. Bauer, H. Wagner, and K. Heeg. 1995. Peptide engineering allows cytotoxic T-cell vaccination against human papilloma virus tumour antigen, E6. Immunology 84:298.
34. Pogue, R., J. Eron, J. Frelinger, and M. Matsui. 1995. Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity. Proc. Natl. Acad. Sci. USA 92:8166.
35. Kawakami, Y., S. Rosenberg, and M. Lotze. 1988. Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma. J. Exp. Med. 168:2183.
36. Topalian, S., D. Solomon, and S. Rosenberg. 1989. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J. Immunol. 142:3714.
37. Rivoltini, L., Y. Kawakami, K. Sakaguchi, S. Southwood, A. Sette, P. Robbins, F. Marincola, M. Salgaller, J. Yannelli, E. Appella, and S. Rosenberg. 1995. Induction of tumor reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J. Immunol. 154:2257.
38. Salter, R., D. Howell, and P. Cresswell. 1985. Genes regulating HLA class 1 antigen expression in T-B lymphoblast hybrids. Immunogenetics 21:235.
39. Kawakami, Y., S. Eliyahu, K. Sakaguchi, P. Robbins, L. Rivoltini, J. Yannelli, E. Appella, and S. A. Rosenberg. 1994. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2 restricted tumor infiltrating lymphocytes. J. Exp. Med. 180:347.
40. Sette, A., J. Sidney, M. del Guercio, S. Southwood, J. Ruppert, C. Dahlberg, H. Grey, and R. Kubo. 1994. Peptide binding to the most frequent HLA-A class 1 alleles measured by quantitative molecular binding assays. Mol. Immunol. 31: 813.
41. Topalian, S., L. Muul, D. Solomon, and S. Rosenberg. 1987. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J. Immunol. Methods 102:127.
42. Sercarz, E., P. Lehmann, A. Ametani, G. Benichou, A. Miller, and K. Moudgil. 1993. Dominance and crypticity of T cell antigenic determinants. Annu. Rev. Immunol. 11:729.
43. Moudgil, K., A. Ametani, I. Grewal, V. Kumar, and E. Sercarz. 1993. Processing of self-proteins and its impact on shaping the T cell repertoire, autoimmunity, and immune regulation. Int. Rev. Immunol. 10:365.
44. Moudgil, K., and E. Sercarz. 1994. Can antitumor immune responses discriminate between self and nonself? Immunol. Today 15:353.
45. Ohno, S. 1992. How cytotoxic T cells manage to discriminate nonself from self at the nonapeptide level. Proc. Natl. Acad. Sci. USA 89:4643.
46. Kawakami, Y., and S. Rosenberg. 1995. Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy. Int. Rev. Immunol. In press.
47. Kawakami, Y., and S. Rosenberg. 1995. T-cell recognition of self peptides as tumor rejection antigens. Immunol Res. In press.
48. Wang, M., V. Bronte, P. Chen, L. Gritz, D. Panicali, S. Rosenberg, and N. Restifo. 1995. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J. Immunol. 154:4685.
49. Bronte, V., K. Tsung, J. Rao, P. Chen, M. Wang, S. Rosenberg, and N. Restifo. 1995. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J. Immunol. 154:5282.
50. Mottez, E., P. Langlade-Demoyen, H. Gournier, F. Martinon, J. Maryanski, P. Kourilsky, and J. Abastado. 1995. Cells expressing a major histocompatibility complex class I molecule with a single covalently bound peptide are highly immunogenic. J. Exp. Med. 181:493.